Functioning Pituitary Adenomas - Current Treatment Options and Emerging Medical Therapies

Overview

Journal Eur Endocrinol

Specialty Endocrinology

Date 2019 Jun 28

PMID 31244908

Citations 25

Authors

Elena V Varlamov

Shirley McCartney

Maria Fleseriu

Affiliations

Soon will be listed here.

Abstract

Pituitary adenomas are benign tumours comprising approximately 16% of all primary cranial neoplasms. Functioning pituitary adenomas (prolactinomas, somatotroph, corticotroph, thyrotroph and rarely gonadotroph adenomas) cause complex clinical syndromes and require prompt treatment to reduce associated morbidity and mortality. Treatment approaches include transsphenoidal surgery, medical therapy and radiation. Medical therapy is the primary therapy for prolactinomas, and surgery by a skilled neurosurgeon is the first-line approach for other functioning pituitary adenomas. A multimodal treatment is frequently necessary to achieve biochemical and clinical control, especially, when surgery is not curative or when medical therapy fails. Several emerging, novel, medical treatments for acromegaly, Cushing's disease and prolactinomas are in phase II and III clinical trials and may become effective additions to the current drug armamentarium. The availability of various management options will allow an individualised treatment approach based on the unique tumour type, clinical situation and patient preference.

Citing Articles

Cabergoline-induced NDFIP1 upregulation in pituitary neuroendocrine tumor cells activates mTOR signaling and contributes to cabergoline resistance.

Gu W, Zhang W, Wu Z, Cai Y J Neurooncol. 2025; .

PMID: 39891847 DOI: 10.1007/s11060-025-04949-7.

Investigating Endocrine Causes in Fluid Non-responsive Hypotension: An Interesting Case of a Pituitary Macroadenoma.

Acharya S, Kumar A Cureus. 2025; 16(12):e75843.

PMID: 39822478 PMC: 11736059. DOI: 10.7759/cureus.75843.

Factors affecting hormonal outcomes in patients undergoing surgery for non-functioning pituitary neuroendocrine tumors: a prospective observational study.

Singh H, Sharma A, Choudhary M, Jain G, Sharma V Neurosurg Rev. 2024; 48(1):4.

PMID: 39725802 DOI: 10.1007/s10143-024-03150-0.

Clinical features of pituitary carcinoma: analysis based on a case report and literature review.

Yang Y, Liang W, Fan K, Yang T, Cheng J Front Endocrinol (Lausanne). 2024; 15:1440247.

PMID: 39544231 PMC: 11560426. DOI: 10.3389/fendo.2024.1440247.

A Peculiar Case of Cabergoline Response to a Non-functioning Cystic Pituitary Adenoma in a Young Adult Male.

Rahman A, Piasecki J, Rogers P, Koo D Cureus. 2024; 16(8):e67927.

PMID: 39221401 PMC: 11365584. DOI: 10.7759/cureus.67927.

References

Nagesser S, VAN SETERS A, Kievit J, Hermans J, Krans H, van de Velde C . Long-term results of total adrenalectomy for Cushing's disease. World J Surg. 1999; 24(1):108-13. DOI: 10.1007/s002689910020. View

LANDOLT A, Haller D, Lomax N, Scheib S, Schubiger O, Siegfried J . Octreotide may act as a radioprotective agent in acromegaly. J Clin Endocrinol Metab. 2000; 85(3):1287-9. DOI: 10.1210/jcem.85.3.6464. View

Kuhn J, Arlot S, Lefebvre H, Caron P, Cortet-Rudelli C, Archambaud F . Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab. 2000; 85(4):1487-91. DOI: 10.1210/jcem.85.4.6548. View

Colao A, Di Sarno A, Landi M, Scavuzzo F, Cappabianca P, Pivonello R . Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab. 2000; 85(6):2247-52. DOI: 10.1210/jcem.85.6.6657. View

Pan L, Zhang N, Wang E, Wang B, Dai J, Cai P . Gamma knife radiosurgery as a primary treatment for prolactinomas. J Neurosurg. 2001; 93 Suppl 3:10-3. DOI: 10.3171/jns.2000.93.supplement. View

Lely A, Hutson R, Trainer P, Besser G, Barkan A, Katznelson L . Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001; 358(9295):1754-9. DOI: 10.1016/s0140-6736(01)06844-1. View

Tashiro H, Katabuchi H, Ohtake H, Yoshioka A, Matsumura S, Suenaga Y . An immunohistochemical and ultrastructural study of a follicle-stimulating hormone-secreting gonadotroph adenoma occurring in a 10-year-old girl. Med Electron Microsc. 2002; 33(1):25-31. DOI: 10.1007/s007950000004. View

Dickerman R, Oldfield E . Basis of persistent and recurrent Cushing disease: an analysis of findings at repeated pituitary surgery. J Neurosurg. 2003; 97(6):1343-9. DOI: 10.3171/jns.2002.97.6.1343. View

Valdes Socin H, Chanson P, Delemer B, Tabarin A, Rohmer V, Mockel J . The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol. 2003; 148(4):433-42. DOI: 10.1530/eje.0.1480433. View

10.

Attanasio R, Barausse M, Cozzi R . Raloxifene lowers IGF-I levels in acromegalic women. Eur J Endocrinol. 2003; 148(4):443-8. DOI: 10.1530/eje.0.1480443. View

11.

Barker 2nd F, Klibanski A, Swearingen B . Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab. 2003; 88(10):4709-19. DOI: 10.1210/jc.2003-030461. View

12.

Mulinda J, Hasinski S, Rose L . Successful therapy for a mixed thyrotropin-and prolactin-secreting pituitary macroadenoma with cabergoline. Endocr Pract. 2004; 5(2):76-9. DOI: 10.4158/EP.5.2.76. View

13.

Leong G, Moverare S, Brce J, Doyle N, Sjogren K, Dahlman-Wright K . Estrogen up-regulates hepatic expression of suppressors of cytokine signaling-2 and -3 in vivo and in vitro. Endocrinology. 2004; 145(12):5525-31. DOI: 10.1210/en.2004-0061. View

14.

Mestron A, Webb S, Astorga R, Benito P, Catala M, Gaztambide S . Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol. 2004; 151(4):439-46. DOI: 10.1530/eje.0.1510439. View

15.

Minniti G, Traish D, Ashley S, Gonsalves A, Brada M . Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab. 2004; 90(2):800-4. DOI: 10.1210/jc.2004-1152. View

16.

Minniti G, Jaffrain-Rea M, Osti M, Esposito V, Santoro A, Solda F . The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol (Oxf). 2005; 62(2):210-6. DOI: 10.1111/j.1365-2265.2005.02199.x. View

17.

Nomikos P, Buchfelder M, Fahlbusch R . The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol. 2005; 152(3):379-87. DOI: 10.1530/eje.1.01863. View

18.

Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes-Socin H . Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol. 2005; 152(1):61-6. DOI: 10.1530/eje.1.01824. View

19.

Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V . A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab. 2005; 90(7):4405-10. DOI: 10.1210/jc.2004-2466. View

20.

Castinetti F, Taieb D, Kuhn J, Chanson P, Tamura M, Jaquet P . Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab. 2005; 90(8):4483-8. DOI: 10.1210/jc.2005-0311. View